Indoco Remedies
273.55
+0.45(+0.16%)
Market Cap₹2,523.44 Cr
PE Ratio126.00
IndustryHealthcare
Company Performance:
1D+0.16%
1M-8.59%
6M+21.94%
1Y-27.94%
5Y+26.73%
View Company Insightsright
Latest news about Indoco Remedies
Indoco Remedies Secures USFDA Approval for Generic Rivaroxaban Tablets Aug 13, 2025
Indoco Remedies Promoters Execute Inter-Group Share Transfer of 28,100 Equity Shares Aug 08, 2025
Indoco Remedies Completes ₹272.1 Crore Sale and Leaseback Transaction for Waluj Facility Equipment Aug 01, 2025
Indoco Remedies Executes Rs 27.21 Crore Sale-Leaseback Deal for Waluj Facility Equipment Aug 01, 2025
More news about Indoco Remedies
24Jul 25
Indoco Remedies Reports Q1 Loss Despite Revenue Growth; Receives EU GMP Certification
Indoco Remedies reported a 12.5% increase in Q1 revenue to Rs 429.08 crore, but faced profitability challenges with a net loss of Rs 36.35 crore. EBITDA improved to Rs 14.80 crore. The company received EU GMP certification for its Goa Plant II, potentially opening new European market opportunities. Two subsidiaries, FPP Holding LLC and Warren Remedies Private Limited, reported losses. Management remains confident about future growth and turnaround prospects.
24Jul 25
Indoco Remedies Secures EU GMP Compliance Certificate for Goa Plant II
Indoco Remedies Limited has received the European Union Good Manufacturing Practice (EU GMP) compliance certificate for its sterile drug manufacturing facility at Goa Plant II. The certification, issued by European Health Authorities, covers the facility located at L32, 33 and 34, Verna Industrial Estate, South Goa-403722. This achievement validates the company's adherence to high-quality manufacturing standards required for pharmaceutical production in the European market. Ms. Aditi Panandikar, Managing Director, emphasized the company's commitment to supplying quality and affordable medicines globally. Indoco Remedies, with an annual turnover of US$ 180.00 million and a workforce of over 6,000, operates 11 manufacturing facilities and has approvals from major regulatory authorities worldwide.
11Jun 25
Indoco Remedies Relieved as GST Authority Drops ₹85 Million Demand
The GST Authority has discontinued legal proceedings against Indoco Remedies, a major pharmaceutical company, effectively nullifying a potential demand of ₹85.00 million (₹8.50 crore). This decision removes a significant financial liability from the company's books, potentially improving its financial outlook and market perception. The resolution allows Indoco Remedies to refocus on its core business operations without the burden of ongoing GST proceedings.
23May 25
Indoco Remedies Secures FDA Approval for Allopurinol Tablets
Indoco Remedies has received final approval from the U.S. Food and Drug Administration (USFDA) for its Allopurinol Tablets USP 200 mg. This approval marks a significant milestone in the company's U.S. market expansion efforts. Allopurinol, used to treat gout and certain kidney stones, represents a new revenue opportunity for Indoco in one of the world's largest pharmaceutical markets. The approval validates the company's manufacturing standards and quality control processes, potentially leading to increased sales and market presence.
22May 25
Indoco Remedies Reports Q4 Loss, Revenue Drop; Shares Slump 7%
Indoco Remedies announced its Q4 financial results, showing a significant downturn. The company reported a consolidated net loss of ₹40.40 crore, contrasting with a profit in the same quarter last year. Revenue decreased by 12.5% to ₹384.00 crore. Despite challenges, a final dividend of ₹0.20 per share was declared. The stock price fell 7% to ₹242.40 following the announcement.
11Mar 25
Indoco Remedies' AnaCipher Facility Completes FDA Inspection with One Form 483
Indoco Remedies' Clinical Research Organisation, AnaCipher, in Hyderabad, completed a U.S. FDA inspection from March 3-7, 2025. The inspection, covering clinical and bioanalytical phases of three BA/BE studies, resulted in one Form 483 observation. The company will respond within the specified timeframe. Managing Director Aditi Kare Panandikar views this as validation of their adherence to regulations and quality standards.
10Mar 25
Indoco Remedies' AnaCipher Facility Completes FDA Inspection with One Form 483 Observation
Indoco Remedies' Clinical Research Organisation, AnaCipher, in Hyderabad completed a 5-day FDA inspection from March 3-7, 2025. The inspection, covering clinical and bioanalytical phases of three BA/BE studies, resulted in one Form 483 observation. The company plans to respond within the given timeframe. Managing Director Aditi Kare Panandikar views this as validation of their adherence to regulations and quality standards.
Indoco Remedies
273.55
+0.45
(+0.16%)
1 Year Returns:-27.94%
Industry Peers
Sun Pharmaceutical
1,593.60
(+0.71%)
Divis Laboratories
6,009.00
(-2.03%)
Cipla
1,553.40
(-1.55%)
Torrent Pharmaceuticals
3,579.10
(-0.56%)
Dr Reddys Laboratories
1,268.10
(+1.21%)
Mankind Pharma
2,550.60
(-0.71%)
Zydus Life Science
1,013.85
(+0.19%)
Lupin
1,943.90
(+0.24%)
Abbott
31,150.00
(-3.19%)
Alkem Laboratories
5,333.50
(+0.60%)